Table 1.
PD-1 pathway blocking drugs currently in clinical testing
| Drug name | Alternative names | Target | Source | Isotype and characteristics |
Regulatory approval |
|---|---|---|---|---|---|
| BMS-936559 | MDX-1105 | PD-L1 | Bristol-Myers Squibb | Fully human lgG4 | pending |
| MEDI0680 | AMP-514 | PD-1 | MedImmune/ AstraZeneca |
Information not available | pending |
| MEDI4736 | none | PD-L1 | Medlmmune/ AstraZeneca |
Fc-modified human lgG1 | pending |
| MPDL3280A | RG7446 | PD-L1 | Genentech/ Roche |
Fc-modified human lgG1 | pending |
| MSB0010718C | none | PD-L1 | EMD Serono | Fully human lgG1 | pending |
| Nivolumab | Opdivo; BMS-936558; MDX-1106; ONO-4538 |
PD-1 | Bristol-Myers Squibb; Ono Pharmaceuticals |
Fully human lgG4 | Treatment-refractory unresectable melanoma (US and Japan) |
| Pembrolizumab | Keytruda; MK-3475; lambrolizumab |
PD-1 | Merck | Humanized lgG4 | Treatment-refractory unresectable melanoma (US) |
| Pidilizumab | CT-011 | PD-1 | CureTech | Humanized lgG1 | pending |